News Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX Other stock markets 11:17:32 2024-05-06 am EDT			5-day change	1st Jan Change
2.065 ^USD	-0.72%		+5.53%	-29.77%

Mar. 25	Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	DJ
Mar. 25	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Esperion to Participate in Upcoming May Investor Conferences	Apr. 29	GL
Esperion to Report First Quarter 2024 Financial Results on May 7	Apr. 23	GL
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL Tablets in Diverse Populations Including Women, Hispanics, Latinx and Patients with Obesity	Apr. 08	AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	Apr. 07	AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	Apr. 07	GL
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	Apr. 01	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be presented at ACC.24	Mar. 26	AQ
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	Mar. 26	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	Mar. 25	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	Mar. 25	AQ
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	Mar. 25	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 25	MT
Esperion - U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 25	AQ
Esperion - CHMP Issues Positive Opinions for both Bempedoic Acid and the Bempedoic Acid, Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	Mar. 25	AQ
Transcript : Esperion Therapeutics, Inc. - Special Call	Mar. 25
Top Premarket Gainers	Mar. 25	MT
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 22	BU
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 22	CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	Mar. 22	MT
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet	Mar. 22	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Summary

Filters